Side Effects Whoopi Goldberg Publicly Discussed (and What They Match in the Clinical Literature)

By
Published Updated Last reviewed
Medication safety clinical consultation image for Side Effects Whoopi Goldberg Publicly Discussed (and What They Match in the Clinical Literature)

At a glance

  • Celebrity: Whoopi Goldberg
  • Drug disclosed: Mounjaro (tirzepatide), a dual GIP/GLP-1 receptor agonist
  • Status: Confirmed by Goldberg herself on The View
  • Drug family: GLP-1 receptor agonist class (specifically a dual incretin)
  • This page's focus: Mapping her publicly described side effects to FDA label data and peer-reviewed trial findings

What Whoopi Goldberg Has Publicly Said

Whoopi Goldberg discussed her use of Mounjaro on ABC's The View, confirming that she had been prescribed the medication for weight management. During on-air segments, she spoke candidly about her experience, including side effects she encountered during treatment. Her willingness to talk about these effects on daytime television gave millions of viewers a first-person account of what starting a GLP-1 class medication can feel like.

Goldberg's disclosure matters for a specific demographic reason. She is an older Black woman discussing a prescription weight-management medication on a show watched predominantly by women over 40. Public health data from the CDC show that obesity prevalence among non-Hispanic Black women exceeds 56%, making real-world accounts from this population especially relevant.

The HealthRX Medical Team emphasizes: a celebrity talking about side effects on television is not medical evidence. But it is a starting point for a clinical conversation. Below, we match what Goldberg has described publicly to what the FDA label and trial data actually show.

Mounjaro: How It Works (Brief Pharmacology)

Tirzepatide, marketed as Mounjaro, is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. It was approved by the FDA in May 2022 for type 2 diabetes and later studied for obesity under the brand name Zepbound.

The drug works through two complementary pathways. GLP-1 receptor activation slows gastric emptying, reduces appetite, and improves insulin secretion. GIP receptor activation appears to enhance the weight-loss effect beyond what GLP-1 alone achieves, though the precise mechanism of GIP's contribution remains an area of active research. A 2022 study published in The New England Journal of Medicine demonstrated that tirzepatide at the highest dose (15 mg) produced mean weight reductions of 20.9% from baseline in the SURMOUNT-1 trial.

This dual mechanism also explains the side effect profile. Because both receptor pathways affect gut motility and satiety signaling, gastrointestinal symptoms are the dominant class of adverse events.

The Side Effects: What the FDA Label Documents

The FDA prescribing information for Mounjaro lists the following adverse reactions occurring in at least 5% of patients at any dose, at rates exceeding placebo:

  • Nausea: reported in 12% to 18% of patients across dose tiers (vs. 4% placebo)
  • Diarrhea: 12% to 17% (vs. 8% placebo)
  • Decreased appetite: 5% to 11% (vs. 1% placebo)
  • Vomiting: 5% to 9% (vs. 2% placebo)
  • Constipation: 6% to 7% (vs. 1% placebo)
  • Dyspepsia: 5% to 8% (vs. 3% placebo)
  • Abdominal pain: 5% to 6% (vs. 4% placebo)

The pattern is consistent across the SURPASS trials (type 2 diabetes population) and the SURMOUNT trials (obesity population). A pooled analysis published in The Lancet confirmed that GI events were the most common reason for treatment discontinuation, though discontinuation rates remained below 7%.

Most of these side effects are dose-dependent. They tend to peak during the titration phase (the first 4 to 8 weeks as the dose escalates from 2.5 mg upward) and diminish for many patients once a stable maintenance dose is reached.

Matching Goldberg's Public Descriptions to the Data

When Goldberg spoke on The View about her Mounjaro experience, the gastrointestinal effects she referenced are consistent with the most commonly reported adverse events in clinical trials. This alignment is not surprising. Nausea and GI discomfort are so prevalent with GLP-1 class drugs that clinicians consider them almost expected during titration.

The HealthRX Medical Team's clinical read: the side effects Goldberg described publicly track with what a prescribing physician would counsel any patient to expect during the dose-escalation period. The fact that she continued treatment and discussed ongoing use suggests these effects were manageable for her, which is also consistent with trial data showing that the majority of patients who experience GI side effects do not discontinue therapy.

One factor worth noting for Goldberg's demographic: older adults (she was born in 1955) may experience slower gastric emptying at baseline. A study in the Journal of the American Geriatrics Society has documented age-related changes in GI motility. When a medication that further slows gastric emptying is added, the subjective experience of nausea or fullness can be more pronounced. Peer-reviewed data on GLP-1 agonists in older populations suggest that slower titration schedules may reduce GI burden in patients over 65.

What the Trials Show About GI Side Effects Over Time

The temporal pattern matters. In the SURMOUNT-1 trial, GI adverse events were most frequent in the first 8 to 12 weeks of treatment. By week 20, the incidence of new-onset nausea had dropped substantially. The trial design itself accounts for this: Mounjaro's label recommends starting at 2.5 mg weekly and increasing by 2.5 mg every four weeks, giving the body time to adjust.

Patients who escalated too quickly or who skipped the lower dose tiers reported more severe symptoms. This is why the HealthRX Medical Team stresses that dose titration is not optional. It is a core part of the treatment protocol designed to minimize exactly the kind of side effects that make headlines when celebrities discuss them.

For the 15 mg dose tier specifically (the highest available), the SURMOUNT-1 data showed nausea in 24% of participants during the treatment period, but fewer than 6% discontinued because of GI events. The gap between "experienced a side effect" and "stopped treatment because of a side effect" is clinically significant and often lost in public conversation.

The Broader Context: GLP-1 Side Effects Across the Class

Tirzepatide's GI side effect rates are comparable to, and in some analyses slightly lower than, those seen with semaglutide (Ozempic/Wegovy). A 2023 meta-analysis published in JAMA Network Open comparing tirzepatide to semaglutide found that both drugs produced similar rates of nausea and vomiting, though tirzepatide's dual-agonist mechanism did not appear to increase GI risk beyond what single-agonist GLP-1 drugs produce.

This is relevant because public conversations often conflate all "weight loss shots" as identical. They are not. Tirzepatide and semaglutide have different receptor binding profiles, different pharmacokinetics, and different labeled indications, even though the most common patient-facing side effects overlap.

Less Common but Serious Adverse Events

The FDA label for Mounjaro also includes warnings for less common but more serious risks that Goldberg has not publicly discussed (and which the HealthRX Medical Team is not attributing to her):

  • Pancreatitis: Cases have been reported in clinical trials. Patients are advised to discontinue if pancreatitis is suspected.
  • Thyroid C-cell tumors: Tirzepatide carries a boxed warning based on animal studies showing thyroid C-cell tumors in rodents. Whether this translates to human risk remains unconfirmed, but the drug is contraindicated in patients with a personal or family history of medullary thyroid carcinoma.
  • Hypoglycemia: Primarily a risk when tirzepatide is combined with insulin or sulfonylureas.
  • Gallbladder events: Cholelithiasis and cholecystitis have been reported at rates exceeding placebo.

These are included here for completeness. The clinical literature does not suggest that any of these serious events are more common in older women specifically, though gallbladder events may warrant monitoring in patients undergoing rapid weight loss regardless of the mechanism.

The HealthRX Medical Team Take

Whoopi Goldberg's on-air discussion of Mounjaro side effects did something that pharmaceutical marketing cannot: it gave a real person's account of what the first weeks on a GLP-1 medication feel like. The side effects she described publicly are the same ones that appear at the top of every tirzepatide trial's adverse-event table. They are real, they are common, and for most patients, they are temporary.

What her account does not replace is individualized medical guidance. The HealthRX Medical Team recommends that any patient considering tirzepatide discuss their complete medical history, current medications, and personal risk factors with a prescribing clinician. Age, baseline GI health, and concurrent medications all influence how a patient will tolerate this drug class.

The normalization of GLP-1 medications on daytime television has value. It reduces stigma. It also carries risk if viewers interpret a celebrity's positive outcome as a guarantee of their own. Side effects are not a design flaw. They are a predictable pharmacological consequence of how these drugs work, and managing them is part of successful treatment.

Frequently asked questions

›
›
›
›
›

References